Robert J. Wong, Ramsey Cheung, Aijaz Ahmed – 25 December 2013 – Nonalcoholic steatohepatitis (NASH) is currently the third leading indication for liver transplantation (LT) in the U.S. and is predicted to become the leading indication for LT in the near future. The trends in NASH‐related hepatocellular carcinoma (HCC) among LT recipients in the U.S. remain undefined. We performed a retrospective cohort study to evaluate trends in the etiology of HCC among adult LT recipients in the U.S. from 2002 to 2012, using national data from the United Network for Organ Sharing registry.

Christoph Höner zu Siederdissen, Sven Pischke, Jerome Schlue, Katja Deterding, Timo Hellms, Susanne Schuler‐Lüttmann, Anke Schwarz, Michael P. Manns, Markus Cornberg, Heiner Wedemeyer – 24 December 2013

Lucio Caccamo, Barbara Antonelli, Giorgio Rossi – 23 December 2013

Fernando Bril, Romina Lomonaco, Beverly Orsak, Carolina Ortiz‐Lopez, Amy Webb, Fermin Tio, Joan Hecht, Kenneth Cusi – 23 December 2013 – Hyperinsulinemia is believed to play a key role in the pathogenesis of nonalcoholic steatohepatitis (NASH) and associated cardiovascular risk. However, the relative contribution of insulin clearance to hyperinsulinemia and its relationship to liver histology have not been carefully evaluated before.

Jeremie Guedj, Jing Yu, Micha Levi, Bin Li, Steven Kern, Nikolai V. Naoumov, Alan S. Perelson – 23 December 2013 – Alisporivir (ALV) is a cyclophilin inhibitor with pan‐genotypic activity against hepatitis C virus (HCV). Here, we characterize the viral kinetics observed in 249 patients infected with HCV genotypes 2 or 3 and treated for 6 weeks with different doses of ALV with or without ribavirin (RBV). We use this model to predict the effects of treatment duration and different doses of ALV plus RBV on sustained virologic response (SVR).

Frank Chen, Ann‐Bin Shyu, Benjamin Shneider – 23 December 2013

Yoon Seok Roh, Surim Park, Jong Won Kim, Chae Woong Lim, Ekihiro Seki, Bumseok Kim – 21 December 2013 – Toll‐like receptor 7 (TLR7) signaling predominantly regulates production of type I interferons (IFNs), which has been suggested in clinical studies to be antifibrotic. However, the mechanistic role of the TLR7‐type I IFN axis in liver fibrosis has not been elucidated. In the present study, liver fibrosis was induced in wild‐type (WT), TLR7‐deficient, and IFN‐α/β receptor‐1 (IFNAR1)‐deficient mice and TLR7‐mediated signaling was assessed in liver cells isolated from these mice.

Kirsten Boonstra, Emma L. Culver, Lucas Maillette de Buy Wenniger, Marianne J. Heerde, Karel J. Erpecum, Alexander C. Poen, Karin M.J. Nieuwkerk, B.W. Marcel Spanier, Ben J.M. Witteman, Hans A.R.E. Tuynman, Nan Geloven, Henk Buuren, Roger W. Chapman, Eleanor Barnes, Ulrich Beuers, Cyriel Y.

Koichi Watashi, Ann Sluder, Takuji Daito, Satoko Matsunaga, Akihide Ryo, Shushi Nagamori, Masashi Iwamoto, Syo Nakajima, Senko Tsukuda, Katyna Borroto‐Esoda, Masaya Sugiyama, Yasuhito Tanaka, Yoshikatsu Kanai, Hiroyuki Kusuhara, Masashi Mizokami, Takaji Wakita – 21 December 2013 – Chronic hepatitis B virus (HBV) infection is a major public health problem worldwide. Although nucleos(t)ide analogs inhibiting viral reverse transcriptase are clinically available as anti‐HBV agents, emergence of drug‐resistant viruses highlights the need for new anti‐HBV agents interfering with other targets.

Chen‐Yen Yang, Xiong Ma, Koichi Tsuneyama, Shanshan Huang, Toru Takahashi, Naga P. Chalasani, Christopher L. Bowlus, Guo‐Xiang Yang, Patrick S.C. Leung, Aftab A. Ansari, Linda Wu, Ross L. Coppel, M. Eric Gershwin – 21 December 2013 – The interleukin (IL)‐12/IL‐23‐mediated Th1/Th17 signaling pathway has been associated with the etiopathogenesis of primary biliary cirrhosis (PBC).